性激素与前列腺癌病理分级及临床分期的相关性

Relationships of sex hormones with pathological grade and clinical stage in patients with prostate cancer

摘要:

目的  探讨前列腺癌（PCa）患者血清性激素睾酮（T）、雌二醇（E2）、孕激素（P）、卵泡刺激素（FSH）、黄体生成素（LH）及泌乳素（PRL）的水平及其与PCa的病理分级及临床分期的相关性。方法  PCa和良性前列腺增生症（BPH）患者各45例，另选取体检健康男性45例为正常对照组。采用电化学发光免疫分析法测定性激素六项（T、E2、P、FSH、LH及PRL）的水平。对PCa患者进行病理分级及临床分期，分析组间差异。评估各检测指标与PCa的病理分级及临床分期的相关性。结果  与BPH组及正常对照组比较，PCa组患者血清T降低、FSH和LH增高，差异有统计学意义（P <0.05），E2、P、PRL比较，差异均无统计意义（P >0.05）；而BPH组患者T、E2、P、FSH、LH及PRL水平与正常对照组比较，差异无统计学意义（P >0.05）。相关性分析结果显示，PCa患者血清T、E2、P、FSH、LH及PRL水平与PCa的病理分级及临床分期均无相关性（P >0.05）。结论  血清T、FSH、LH水平对前列腺良、恶性疾病的鉴别有指导意义。PCa患者血清各项性激素水平与PCa病理分级及临床分期无相关性。

Abstract:

Objective To explore serum sex hormone T, FSH, LH, E2, P and PRL levels and their relationships with pathological grade and clinical stage in patients with prostate cancer (PCa). Methods Forty-five patients with PCa (PCa group), 45 cases of benign prostatic hyperplasia (BPH group), 45 cases of medical healthy men (normal control group) were selected into the study. The serum sex hormone (T, FSH, LH, E2, P and PRL) levels were determined by electrochemiluminescent immunoassay. Pathological grading and clinical staging in the patients with PCa were carried out and the differences between the groups were analyzed. The relationships of each test indicator with pathological grade and clinical stage were evaluated. Results Compared with the BPH and and control groups, the serum T level decreased, and FSH and LH significantly increased in the PCa group (P < 0.05); while E2, P or PRL level had no significant difference (P > 0.05). But compared with the normal control group, T, FSH, LH, E2, P or PRL level was not significantly different in the BPH group (P > 0.05). Correlation analysis showed that serum T, FSH, LH, E2, P or PRL level was not significantly correlated with pathological grade or clinical stage in the PCa group (P > 0.05). Conclusions The serum T, FSH and LH levels have directive significance for identification of PCa and benign prostate diseases. The serum level of each sex hormone in the patients with PCa is not significantly correlated with pathological grade or clinical stage.